Endocrine Abstracts

Introduction: Denosumab is a human monoclonal antibody against the receptor activator of nuclear factor-kB ligand, to reduce bone resorption by limiting maturation of osteoclasts. It has been approved for use in Scotland in patients with a bone mineral density (BMD) T-score of between −4 to 2.5 who are unable to take bisphosphonates. We aimed to analyze the effects of denosumab on BMD and fracture rate in a cohort of patients who have completed a 3-year cycle of...

Case History: A 79 year old gentleman sustained a traumatic fracture of his left humerus in November 2016. Given his age and non-union of fracture, he was referred for a dual X-ray absorptiometry (DXA) scan in May 2017. This demonstrated markedly elevated bone mineral density (BMD) and subsequent investigation was performed.The patient has a past medical history of type 2 diabetes mellitus, hypertension, asthma and kidney stones. H...

Introduction: Denosumab is a human monoclonal antibody against the receptor activator of nuclear factor-kB ligand, to reduce bone resorption by limiting maturation of osteoclasts. It has been approved for use in Scotland in patients with a bone mineral density (BMD) T-score of between −4 to 2.5 who are unable to take bisphosphonates. We aimed to analyze the effects of denosumab on BMD and fracture rate in a cohort of patients who have completed a 3-year cycle of...

Case History: A 79 year old gentleman sustained a traumatic fracture of his left humerus in November 2016. Given his age and non-union of fracture, he was referred for a dual X-ray absorptiometry (DXA) scan in May 2017. This demonstrated markedly elevated bone mineral density (BMD) and subsequent investigation was performed.The patient has a past medical history of type 2 diabetes mellitus, hypertension, asthma and kidney stones. H...